Search clinical trials for: 90Y Ibritumomab tiuxetan

Total 852 results

Chulalongkorn University
Bayer

Terminated

Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

Thailand
Institut fuer anwendungsorientierte Forschung und...

Completed

A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas (escZ-BEAM)

Primary Non-Hodgkin-Lymphoma | Refractory Non-Hodgkin-Lymphoma | CD20+ Aggressive Non-Hodgkin's Lymphoma

Germany
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Waldenström Macroglobulinemia | Post-transplant Lymphoproliferative Disorder | Stage III Adult Burkitt Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Burkitt Lymphoma | Stage IV Adult Diffuse...

United States
Spectrum Pharmaceuticals, Inc
Bayer

Completed

Zevalin Post-marketing Surveillance in Japan (ZEVALIN-DUI)

Non-Hodgkin's Lymphoma (NHL)

Japan
Bayer

Completed

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Lymphoma, Follicular | Non-Hodgkin Lymphoma

Belgium
Case Comprehensive Cancer Center

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

Primary Central Nervous System Non-Hodgkin Lymphoma

United States
Gruppo Italiano Multiregionale per lo studio dei...
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Zevalin Twice in Aggressive Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Italy
Stanford University
National Institutes of Health (NIH); Biogen

Completed

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

Lymphoma, Non-Hodgkin | Blood and Marrow Transplant (BMT)

United States
AHS Cancer Control Alberta

Withdrawn

Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL

Lymphoma

Canada
Soroka University Medical Center

Unknown

Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma (Zevalin)

Non-Hodgkin's Lymphoma

Israel
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone... and other conditions

United States
Northwestern University
Robert H. Lurie Cancer Center

Terminated

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Lymphoma

United States
Bayer

Completed

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Italy, Canada, Switzerland, Netherlands, United Kingdom, Portugal, Germany, Sweden, Denmark, Norway
University of Arizona
National Cancer Institute (NCI)

Completed

Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Anaplastic Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Post-transplant Lymphoproliferative Disorder | Recurrent Childhood Large Cell Lymphoma | Recurrent Childhood Lymphoblastic Lymphoma | Recurrent Childhood Small Noncleaved Cell Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | AIDS-related Peripheral/Systemic Lymphoma | AIDS-related...

United States
Alnylam Pharmaceuticals

Active, not recruiting

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (ILLUMINATE-B)

Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria

United States, France, United Kingdom, Israel, Germany
Bayer

Completed

Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan (ZEVALIN-SDUI)

Non-Hodgkin's Lymphoma (NHL)

Japan
Oslo University Hospital

Completed

Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma

Mantle Cell Lymphoma

Norway
Alnylam Pharmaceuticals

Approved for marketing

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

Primary Hyperoxaluria

Belgium
M.D. Anderson Cancer Center
Biogen

Completed

Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

United States
Alnylam Pharmaceuticals

Active, not recruiting

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)

Primary Hyperoxaluria Type 1 | Primary Hyperoxaluria

United States, Italy, France, Lebanon, Belgium, Netherlands, Israel, United Arab Emirates, Australia, Jordan, Turkey
Spectrum Pharmaceuticals, Inc

Terminated

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Follicular Lymphoma

United States
Spectrum Pharmaceuticals, Inc

Terminated

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
University Hospital, Bordeaux
Bayer

Completed

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) (ZEVALLO)

Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

France
The Christie NHS Foundation Trust
Bayer

Completed

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma (FIZZ)

Follicular Lymphoma

United Kingdom, France
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
University of Alabama at Birmingham
National Cancer Institute (NCI); Biogen

Completed

Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Tufts Medical Center
Spectrum Pharmaceuticals, Inc

Terminated

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

Multiple Myeloma

United States
Sheba Medical Center
City of Hope Medical Center; Amsterdam UMC, location VUmc; University of Göttingen

Completed

Zevalin-beam for Aggressive Lymphoma

Non-Hodgkin's Lymphoma

United States, Netherlands, Germany, Israel
Spectrum Pharmaceuticals, Inc
Bayer

Terminated

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

Lymphoma, Large Cell, Diffuse

Sweden, United States, Italy, Korea, Republic of, Spain, United Kingdom, Hungary, Poland, Finland, Canada, France, Germany, Portugal, Thailand, Belgium, Austria, Ireland, Singapore, Switzerland
McGill University
McGill University Health Centre/Research Institute of the McGill University...

Unknown

Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma (Zevalin)

Non-Hodgkin's Lymphoma

Canada
Lund University Hospital
Bayer

Completed

High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma (HITT)

B-cell Lymphoma

Sweden
Chonnam National University Hospital
Chonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaborators

Completed

90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

Korea, Republic of
University of Wisconsin, Madison
Genentech, Inc.

Terminated

Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

Non-Hodgkin's Lymphoma

United States
Biogen

Completed

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin | Lymphoma, Low-Grade

United States
M.D. Anderson Cancer Center
Biogen

Terminated

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Lymphoma

United States
Boehringer Ingelheim

Completed

Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis

Pharyngitis

South Africa
University of Bologna

Completed

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy (FM+R-Z)

Follicular Lymphoma

Italy
Mayo Clinic
National Cancer Institute (NCI)

Completed

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent... and other conditions

United States
The Cleveland Clinic

Completed

External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

Lymphoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
University of Nebraska
Biogen

Completed

Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation

Lymphoma

United States
Beth Israel Deaconess Medical Center

Terminated

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Grupo Oncológico para el Tratamiento y el Estudio...

Unknown

Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma (GOTEL-FL1LC)

Follicular Lymphoma

Spain
M.D. Anderson Cancer Center
Biogen; CTI BioPharma

Completed

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Lymphoma

United States
Boehringer Ingelheim

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers

Healthy

Search clinical trials for: 90Y Ibritumomab tiuxetan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations